Abstract Details

Title Choosing Multiple Headache Preventive Medications Wisely: A Comprehensive Analysis Of Reported Versus Theoretical Drug-Drug Interactions

Topic Headache

Presentation(s) P8 - Poster Session 8 (11:45 AM-12:45 PM)

Poster/Presentation
Number 15-002

Objective Refractory headache management requires rational polypharmacy when utilizing multiple preventive medications to avoid drug-drug interactions.

Background We seek to generate a comprehensive list of combination preventive headache medications that do not have reported or theoretical drug-drug interactions.

Design/Methods

Preventive medications were taken from Szperka et al's Migraine Care in the Era of COVID-19 and The AHS Position Statement On Integrating New Migraine Treatments Into Clinical practice. We used this list to screen for any interactions between two preventive medications through DrugBank and FAERS data from October 2012 to March 2020.

All possible combinations of preventive medications up to four medications were generated. Using the list of interactions from DrugBank and FAERS, we obtain lists of all possible non-interacting prevention combinations.

Results A total of 23 preventive medications were included in our analysis. From this a total of 182 and 3728 unique combinations of non-interacting preventive medications can be obtained from DrugBank and FAERS, respectively. There are no four drug combinations that have no interaction in DrugBank, while there are 2626 four drug combinations without interaction in FAERS. There are 88 three drug combinations that have no interaction in DrugBank, while there are 907 three drug combinations in FAERS.

Conclusions This is an extension study from our prior study - Victor et al, Estimating Risk of Reported Versus Theoretical Drug-Drug Interactions in Headaches Medicine - presented in AHS/IHC 2021. This study shows that DrugBank is significantly more conservative in terms of estimating interactions when compared to empirical observations. Furthermore our study presents 182 preventive combinations without any known theoretical interaction which may be useful for clinicians when deciding on medication management.

Authors/Disclosures
Ian Hakkinen, MBBS (Evergreen Health) PRESENTER	Dr. Hakkinen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Hakkinen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Hakkinen has a non-compensated relationship as a Co-Founder with MigraLearn.AI that is relevant to AAN interests or activities.
Jay Dave, DO	Dr. Dave has nothing to disclose.
Pengfei Zhang, MD	Dr. Zhang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alder. Dr. Zhang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boardvitals . Dr. Zhang has received stock or an ownership interest from Cymbeline. Dr. Zhang has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��